Selective RXR modulators for the treatment of type II diabetes

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 6, 2002, Pages 974-985

  Faul, Margaret M ^a   Grese, Timothy A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

RXR agonists; RXR modulators; RXR:PPAR heterodimer; Type II diabetes

Indexed keywords

3 METHYL 7 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 3 PROPOXY 2 NAPHTHYL) 2,4,6 OCTATRIENOIC ACID; 4 [2,3 (2,5 DIMETHYL 2,5 HEXANO) 5 METHYL 5H DIBENZO[B,E][1,4]DIAZEPIN 11 YL]BENZOIC ACID; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; AGN 194204; ANTIDIABETIC AGENT; BEXAROTENE; DIMER; GW 0791; HX 531; LG 100324; LG 101392; LG 101506; PA 451; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; DRUG CLASSIFICATION; DRUG CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; HUMANS; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS; TRANSCRIPTION FACTORS;

EID: 0036868282     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Schulman IG, Crombie D, Bissonnette RP, Cesario R, Roegner K, Shao G, Heyman RA: RXR-specific agonists and modulators: A new retinoid pharmacology. Handbook Exp Pharmacol (1999) 139:215-235. A good description of the current understanding of RXR pharmacology at receptor level
2. Kagechika H: Novel synthetic retinoids and separation of the pleiotropic retinoidal activities. Curr Med Chem (2002) 9:591-608.
3. Nagpal S, Chandraratna RA: Recent developments in receptor-selective retinoids. Curr Pharm Design (2000) 6:919-931.
4. Thacher SM, Vasudevan J, Chandraratna RA: Therapeutic applications for ligands of retinoid receptors. Curr Pharm Design (2000) 6:25-58.
5. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Patemiti JR Jr et at. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (1997) 386:407-410. First discussion of the effects of RXR agonists in diabetic animal models.
6. Lenhard JM, Lancaster ME, Paulik MA, Weiel JE, Binz JG, Sundseth SS, Gaskill BA, Lightfoot RM, Brown HR: The RXR agonist LG100268 causes hepatomegaly, improves glycemic control, and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic β-cell dysfunction. Diabetologia (1999) 42:545-554.
7. Patemiti JR Jr, Mukherjee R: The PPAR/RXR heterodimer: Therapeutic target for insulin iresistance and obesity. In: Nutrition, Genetics and Obesity: Pennington Center Nutrition Series. Louisiana State University Press, LA, USA (1999) 9:477-492.
8. Liu YL, Sennitt MV, Hislop DC, Crombie DL, Heyman RA, Cawthome MA: Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats. Int J Obes Relat Metab Disord (2000) 24:997-1004.
9. Singh Ahuja H, Liu S, Crombie DL, Boehm M, Leibowitz MD, Heyman RA, Depre C, Nagy I., Tontonoz P, Davies PJ: Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol Pharmacol (2001) 59:765-773.
10. Vuligonda V, Thacher SM, Chandraratna RA: Enantioselective syntheses of potent retinoid X receptor ligands: Differential biological activities of individual antipodes. J Med Chem (2001) 44:2298-2303.
11. Murray A, Hansen JB, Christensen BV: A novel synthesis of 9-cis-retinoic acid and tagretin analogues via the Pauson-Khand or Heck reaction. Tetrahedron (2001) 57:7383-7390.
12. Miller AB, Lenhard JM, Xu HE, Gampe RT Jr, Montana VG, McDougald DL, Dwomik K, Ittoop OR, Ayscue A, Lin J et al. Structure based design of a potent RXR agonist. 223rd ACS National Meeting, Orlando, FL, USA (2002):MEDI-006.
13. Singh Ahuja H, Liu S, Crombie DL, Boehm M, Leibowitz MD, Heyman RA, Depre C, Nagy L, Tontonoz P, Davies PJA: Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol Pharmacol (2001) 59:765-773.
14. Liu S, Ogilvie KM, Klausing K, Lawson MA, Jolley D, Li D, Bilakovics B, Pascual B, Hein N, Urcan M, Leibowitz MD: Mechanism of selective RXR agonist-induced hypothyroidism in the rat. Endocrinology (2002) 143:2880-2885.
15. Howell SR, Shirley MA, Grese TA, Neel DA, Wells KE, Ulm EH: Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors. Drug Metab Dispos (2001) 29:990-998.
16. Canan Koch SS, Dardashti LJ, Hebert JJ, White SK, Croston GE, Flatten KS, Heyman RA, Nadzan AM: Identification of the first retinoid X receptor homodimer antagonist. J Med Chem (1996) 39:3229-3234.
17. Lala DS, Mukherjee R, Schulman IG, Koch SS, Dardashti LJ, Nadzan AM, Croston GE, Evans RM, Heyman RA: Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature (1996) 383:450-453. First example of the differentiation of homodimer activity from heterodimer activity.
18. Cesario RM, Klausing K, Razzaghi H, Crombie D, Rungta D, Heyman RA, Lala DS: The rexinoid LG100754 is a novel RXR:PPARγ agonist and decreases glucose levels in vivo. Mol Endocrinol (2001) 15:1360-1369.
19. Mapes CM, Ardecky RJ, Boehm MF, Chen JH, D'Arrigo J, Grese TA, Karanewsky DS, Leibowitz MD, Liu S, Ogilvie KM et al. Design and synthesis of new locked-dienoic acid RXR modulators. J Med Chem (2003) manuscript submitted.
20. Michellys PY, Ardecky RJ, Chen JH, Crombie DL, Etgen G, Faul M, Faulkner AL, Grese TA, Heyman RA, Karanewsky DS et al: Small molecule RXR modulators for type 2 diabetes. J Med Chem (2003) manuscript submitted.
21. Ebisawa M, Umemiya H, Ohta K, Fukasawa H, Kawachi E, Christoffel G, Gronemeyer H, Tsuji M, Hashimoto Y, Shudo K, Kagechika H: Retinoid X receptor-antagonistic diazepinylbenzoic acids. Chem Pharm Bull (1999) 47:1778-1786.
22. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, Komeda K, Miki H, Kubota N, Terauchi Y, Tsuchida A et at. Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest (2001) 108:1001-1013. In-depth description of biological activity for the benzodiazepine series of RXR modulators.
23. Takahashi B, Ohta K, Kawachi E, Fukasawa H, Hashimoto Y, Kagechika H: Novel retinoid X receptor antagonists: Specific inhibition of retinoid synergism in RXR-RAR hiterodimer actions. J Med Chem (2002) 45:3327-3330.
24. Hurst RE: Bexarotene (Ugand Pharmaceuticals). Curr Opin Investig Drugs (2000) 1:514-523.
25. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, Suto CM, Goldman ME, Heyman RA: Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem (1994) 37:2930-2941.
26. Koch-Oanan SS, Dardashti L J, Cesario RM, Croston GE, Boehm MF, Heyman RA, Nadzan AM: Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells. J Med Chem (1999) 42:742-750.
27. Faul MM, Ratz AM, Sullivan KA, Trankle WG, Winneroski LL: Synthesis of novel retinoid X receptor-selective retinoids. J Org Chem (2001) 66:5772-5782.
28. Abele E, Lukevics E: Recent advances in the chemistry of oximes. Organic Prep Proced Int (2000) 32:235-264.
29. Vuligonda V, Lin Y, Chandraratna RAS: Synthesis of highly potent RXR-specific retinoids: The use of a cyclopropyl group as a double bond isostere. Bioorg Med Chem Lett (1996) 6:213-218.
30. Yue X, Qing F-L, Sun H, Fan J: A Suzuki coupling approach to double bonds locked analogs of strobilurin A. Tetrahedron Lett (1996) 37:8213-8216.
31. Beard RL, Chandraratna RA, Colon DF, Gillett SJ, Henry E, Mader DK, Song T, Denys L, Garst ME, Taghreed A et al. Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids. J Med Chem (1995) 38:2820-2829.
32. Dawson MI, Jong L, Hobbs PD, Cameron JF, Chao WR, Pfahl M, Lee MO, Shroot B, Pfahl M: Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity. J Med Chem (1995) 38:3368-3383.
33. Hamann LG: An efficient, stereospecific synthesis of the dimer-selective retinoid X receptor modulator (2E,4E,6Z)-7-[5,6,7,8-tetrahydro-5,5,8,8- tetramethyl-2-(n-propyloxy)naphthalen-3-yl]-3-methyl octa-2,4,6-trienoic acid. J Org Chem (2000) 65:3233-3235.
34. Cookson RC, Sharma M, Wilkinson RJ: Aromatic musks derived from 1,2,3,4-tetrahydro-1,1,4,4,6,7-hexamethylnaphthalene. J Chem Soc Perkin Trans 1 (1976) 2:195-200.
35. NOVO NORDISK A/S (Murray A, Hansen JB): Preparation of tetrahydronaphthalene-containing carboxylic acids as RXR receptor agonists for treatment of NIDDM. WO-09958486 (1999).
36. LIGAND PHARMACEUTICALS INC (Boehm MF, Heyman RA, Zhi L): Compounds having selectivity for retinoid X receptors. WO-09321146 (1993).